True Bearing Diagnostics, Inc

11:30 AM - 11:45 AM, Tuesday, October 22, 2019 ・ 2nd Floor
True Bearing Diagnostics has developed TruCAD, the world’s first highly accurate RNA based blood-test diagnostic tool designed for the early-detection of coronary artery disease (CAD).

At a fraction of the cost of coronary catheterization or nuclear imaging, the Company believes TruCAD is positioned to transform the coronary diagnostics industry. True Bearing was founded in 2015 to extend and commercialize certain research breakthroughs developed by the St. Laurent Institute and George Washington University’s Center for Genomic Medicine.

The Company´s mission is to introduce a collection of RNA-based blood tests that will drastically decrease the costs associated with the early-detection and treatment of multiple diseases. For example, in addition to TruCAD, True Bearing is developing bio-marker panels that it believes will revolutionize the diagnosis of biofilm, appendicitis, pneumonia, and other diseases.
Company Type:
Company HQ State:
District Of Columbia  
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
TruCAD
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
one